Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Case Comprehensive Cancer Center, Euclid, OH, USA.
Exp Suppl. 2022;113:189-217. doi: 10.1007/978-3-030-91311-3_7.
Myeloid-derived suppressor cells (MDSCs) are immature bone marrow-derived suppressive cells that are an important component of the pathological immune response associated with cancer. Expansion of MDSCs has been linked to poor disease outcome and therapeutic resistance in patients with various malignancies, making these cells potential targets for next-generation treatment strategies. MDSCs are classified into monocytic (M-MDSC) and polymorphonuclear/granulocytic (PMN-MDSC) subtypes that undertake distinct and numerous roles in the tumor microenvironment or systemically to drive disease progression. In this chapter, we will discuss how MDSC subsets contribute to the growth of primary tumors and induce metastatic spread by suppressing the antitumor immune response, supporting cancer stem cell (CSC)/epithelial-to-mesenchymal transition (EMT) phenotypes and promoting angiogenesis. We will also summarize the signaling networks involved in the crosstalk between cancer cells and MDSCs that could represent putative immunotherapy targets.
髓系来源的抑制细胞（MDSCs）是不成熟的骨髓来源的抑制细胞，是与癌症相关的病理性免疫反应的重要组成部分。MDSCs 的扩增与各种恶性肿瘤患者的不良疾病结局和治疗耐药性有关，使这些细胞成为下一代治疗策略的潜在靶点。MDSCs 分为单核细胞（M-MDSC）和多形核/粒细胞（PMN-MDSC）亚群，它们在肿瘤微环境或全身中发挥不同的、众多的作用，以推动疾病的进展。在本章中，我们将讨论 MDSC 亚群如何通过抑制抗肿瘤免疫反应、支持癌症干细胞（CSC）/上皮间质转化（EMT）表型和促进血管生成来促进原发性肿瘤的生长和诱导转移扩散。我们还将总结癌细胞与 MDSC 之间相互作用涉及的信号网络，这些网络可能代表潜在的免疫治疗靶点。
